Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Conditions: Solid Tumor, Adult; Squamous Cell Carcinoma of Head and Neck; Colorectal Adenocarcinoma; Metastatic Solid Tumor; Recurrent Solid Tumor; Head and Neck Cancer
Interventions: Drug: NT219; Drug: NT219 and ERBITUX® – Dose Escalation; Drug: NT219 and ERBITUX® – Expansion
Sponsor: TyrNovo Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 23, 2020 / by ClinicalTrials.gov / in Oncology

Comments